Cell and gene therapy reimbursement rate

STO-REC-STAT7J64CQT3 Research
42%

European Union · April 2023

Cell and gene therapy reimbursement rate in the European Union stood at 42% in April 2023 (IQVIA).

Original source
Publisher
IQVIA
Authority tier
T3 Research
Locator
Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP
Retrieved
15 Sep 2026
Status
Verified

What the source says

Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.

Verbatim extraction verified: The figure 42% is directly attested in the quoted passage (Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X
MLA
IQVIA Institute. "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios." 2023, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X.
Chicago
IQVIA Institute. "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios." 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X.
BibTeX
@misc{iqvia2023cellt5kh2x, author = {{IQVIA Institute}}, title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios}, year = {2023}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STAT7J64CQ T3 Research

Primary Source

Publisher
IQVIA Institute · homepage ↗
Authority tier
Tier 3 · Industry & Research
Report
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios
Type
Press release
Published
Locator
Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP
Retrieved
15 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_7J64CQDPE38R0DC4ACBET5KH2X